Cite
Rituximab in a risk‐adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte‐predominant Hodgkin lymphoma.
MLA
Della Pepa, Roberta, et al. “Rituximab in a Risk‐adapted Treatment Strategy Gives Excellent Therapeutic Results in Nodular Lymphocyte‐predominant Hodgkin Lymphoma.” British Journal of Haematology, vol. 182, no. 5, Sept. 2018, pp. 715–18. EBSCOhost, https://doi.org/10.1111/bjh.14856.
APA
Della Pepa, R., Picardi, M., Giordano, C., Zacheo, I., Pugliese, N., Cerchione, C., Raimondo, M., Di Perna, M., Troncone, G., Ciancia, G., Intrieri, M., & Pane, F. (2018). Rituximab in a risk‐adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte‐predominant Hodgkin lymphoma. British Journal of Haematology, 182(5), 715–718. https://doi.org/10.1111/bjh.14856
Chicago
Della Pepa, Roberta, Marco Picardi, Claudia Giordano, Irene Zacheo, Novella Pugliese, Claudio Cerchione, Marta Raimondo, et al. 2018. “Rituximab in a Risk‐adapted Treatment Strategy Gives Excellent Therapeutic Results in Nodular Lymphocyte‐predominant Hodgkin Lymphoma.” British Journal of Haematology 182 (5): 715–18. doi:10.1111/bjh.14856.